{"entity":{"id":"tracc","kind":"trial","name":"TRACC","aka":["Tracking mutations in cell free tumour DNA to predict relapse in early colorectal cancer"],"tldr":"A UK study following 1,000 people after bowel cancer surgery with repeated blood tests for tumour DNA, to see how well a positive predicts the cancer coming back and whether the result can guide chemotherapy.","summary":"TRACC is the Royal Marsden-led UK programme tracking ctDNA after surgery for early colorectal cancer. The registry lists it as an observational study of 1,000 participants that started on 5 December 2016, still recruiting, with a primary completion date of 31 July 2029 and study completion of 31 July 2031. It is one of the three large national colorectal programmes (with CIRCULATE-Japan and CIRCULATE-US) whose readouts decide whether ctDNA-guided adjuvant therapy becomes standard outside a trial.","status":"recruiting","asOf":"2026-09-21","links":[{"label":"ClinicalTrials.gov NCT04050345","url":"https://clinicaltrials.gov/study/NCT04050345"}],"tags":["ctdna-roadmap"],"related":["dynamic","circulate-japan","circulate-us","ctdna-tests"],"cancers":["colorectal"],"sections":[],"technologies":["mrd-testing","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":["royal-marsden"],"pathways":[],"terms":["mrd","ctdna"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04050345","phase":"observational","setting":"Early colorectal cancer after curative surgery in the United Kingdom: serial ctDNA to predict relapse, with a later part that uses the result to guide adjuvant chemotherapy","sponsor":"Royal Marsden NHS Foundation Trust","enrolled":1000,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/tracc/","neighbours":{"trial":[{"id":"circulate-japan","kind":"trial","name":"CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)","route":"/trials/circulate-japan/"},{"id":"circulate-us","kind":"trial","name":"CIRCULATE-US","route":"/trials/circulate-us/"},{"id":"dynamic","kind":"trial","name":"DYNAMIC","route":"/trials/dynamic/"}],"roadmap":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/"}],"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"institution":[{"id":"royal-marsden","kind":"institution","name":"The Royal Marsden","route":"/institutions/royal-marsden/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"}]}}